TRxADE HEALTH (DB:4e+40) - Cotización, noticias y análisis

Resumen de acción 4e+40

TRxADE HEALTH, Inc. operates as a health services information technology (IT) company in the United States.

4e+40 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Recompensas

Análisis de riesgos

Los beneficios han disminuido un 49.8% al año en los últimos 5 años

No tiene una capitalización de mercado significativa (€9M)

Patrimonio neto negativo

Los accionistas han sido diluidos sustancialmente en el último año

+ 1 riesgos adicionales

Competidores de TRxADE HEALTH, Inc.

ifa systems

HMSE:IS8

€8.3m

ifa systems

XTRA:IS8

€7.3m

DocCheck

XTRA:AJ91

€45.9m

MeVis Medical Solutions

XTRA:M3V

€48.0m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for TRxADE HEALTH
Historical stock prices
Current Share Price	US$6.86
52 Week High	US$20.01
52 Week Low	US$0.0015
Beta	1.9
1 Month Change	0%
3 Month Change	70.70%
1 Year Change	-65.69%
3 Year Change	-88.95%
5 Year Change	n/a
Change since IPO	-90.85%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	4e+40	DE Healthcare Services	Mercado DE
7D	0%	1.0%	-1.0%
1Y	-65.7%	-23.9%	2.0%

Rentabilidad vs. Industria: 4E40 obtuvo unos resultados inferiores a los del sector German Healthcare Services , que el año pasado arrojó un rendimiento del -24.7%.

Rentabilidad vs. Mercado: 4E40 obtuvo unos resultados inferiores a los del mercado German, que fue del -0.3% el año pasado.

Volatilidad de los precios

Is 4e+40's price volatile compared to industry and market?
4e+40 volatility
4e+40 Average Weekly Movement	n/a
Healthcare Services Industry Average Movement	3.6%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.3%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: El precio de las acciones de 4E40 ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de 4E40 en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2010	34	Suren Ajjarapu	www.trxadehealth.com

Resumen de fundamentos de TRxADE HEALTH, Inc.

¿Cómo se comparan los beneficios e ingresos de TRxADE HEALTH con su capitalización de mercado?
Estadísticas fundamentales de 4e+40
Capitalización bursátil	€8.74m
Beneficios(TTM)	-€3.49m
Ingresos (TTM)	€8.83m

1.0x

Ratio precio-ventas (PS)

-2.5x

Ratio precio-beneficio (PE)

¿Está 4e+40 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 4e+40
Ingresos	US$9.43m
Coste de los ingresos	US$4.16m
Beneficio bruto	US$5.27m
Otros gastos	US$9.00m
Beneficios	-US$3.73m

Últimos beneficios comunicados

Jun 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-2.99
Margen bruto	55.91%
Margen de beneficio neto	-39.55%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado 4e+40 a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción 4e+40

Recompensas

Análisis de riesgos

Competidores de TRxADE HEALTH, Inc.

HMSE:IS8

€8.3m

XTRA:IS8

€7.3m

XTRA:AJ91

€45.9m

XTRA:M3V

€48.0m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

TRxADE HEALTH, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

TRxADE HEALTH, Inc. announced delayed annual 10-K filing

Superlatus Foods, Inc. acquired Superlatus, Inc from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.000001 million.

TRxADE HEALTH Receives Notice from Nasdaq Regarding Non-Compliance with the Timely Filing Requirement for Continued Listing Under Nasdaq Listing Rule 5250(c)(1)

TRxADE HEALTH, Inc. announced delayed 10-Q filing

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding agreement to acquire The Urgent Company, Inc. from Perfect Day, Inc.

Recent updates

TRxADE HEALTH, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

TRxADE HEALTH, Inc. announced delayed annual 10-K filing

Superlatus Foods, Inc. acquired Superlatus, Inc from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.000001 million.

TRxADE HEALTH Receives Notice from Nasdaq Regarding Non-Compliance with the Timely Filing Requirement for Continued Listing Under Nasdaq Listing Rule 5250(c)(1)

TRxADE HEALTH, Inc. announced delayed 10-Q filing

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding agreement to acquire The Urgent Company, Inc. from Perfect Day, Inc.

TRxADE HEALTH, Inc. to Report Q2, 2023 Results on Aug 14, 2023

TRxADE HEALTH Receives Non-Compliance Notice from Nasdaq

TRxADE HEALTH, Inc. (NasdaqCM:MEDS) entered into a binding letter of intent to acquire Superlatus, Inc.

TRxADE HEALTH, Inc., Annual General Meeting, Jun 15, 2023

TRxADE HEALTH Submits Hearing Request to the Nasdaq Hearings Panel

TRxADE HEALTH Receives A Delist Determination Letter from Nasdaq

Wood Sage, LLC entered into a membership interest purchase agreement to acquire Community Specialty Pharmacy, LLC from TRxADE HEALTH, Inc. (NasdaqCM:MEDS) for $0.1 million.

Wood Sage, LLC entered into Membership Interest Purchase Agreement to acquire Alliance Pharma Solutions, LLC for $0.125 million.

TRxADE HEALTH, INC Announces Board Changes

TRxADE HEALTH Receives Written Notice from Nasdaq

Less than half of directors are independent

Third quarter 2022 earnings released: US$0.061 loss per share (vs US$0.16 loss in 3Q 2021)

TRxADE HEALTH, Inc. to Report Q3, 2022 Results on Nov 07, 2022

No longer forecast to breakeven

TRxADE HEALTH Provides Update on Retaining Compliance Regarding Listing

Less than half of directors are independent

Trxade Health, Inc. Appoints Mr. Jeff Newell to Its Board of Directors, Member of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee

TRxADE HEALTH, Inc. Announces the Resignation of Christine L. Jennings as Member of the Board of Directors

TRxADE HEALTH, Inc. Appoints Jeff Newell to Its Advisory Board

TRxADE HEALTH Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings released: US$0.13 loss per share (vs US$0.32 loss in 2Q 2021)

TRxADE HEALTH, Inc. to Report Q2, 2022 Results on Jul 25, 2022

First quarter 2022 earnings released: US$0.12 loss per share (vs US$0.081 loss in 1Q 2021)

No longer forecast to breakeven

TRxADE HEALTH, Inc. to Report Q1, 2022 Results on May 09, 2022

TRxADE HEALTH, Inc., Annual General Meeting, Jun 02, 2022

TRxADE HEALTH, Inc. Announces Management Changes

Full year 2021 earnings released: US$0.65 loss per share (vs US$0.33 loss in FY 2020)

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.017 profit in 3Q 2020)

Second quarter 2021 earnings released: US$0.32 loss per share (vs US$0.072 loss in 2Q 2020)

Independent Director Pamela Tenaerts has left the company

Independent Director Michael Peterson has left the company

Trxade Group, Inc. (NasdaqCM:MEDS) entered into an agreement to acquire QualityCare Pharmacies.

First quarter 2021 earnings released: US$0.081 loss per share (vs US$0.026 profit in 1Q 2020)

Full year 2020 earnings released: US$0.33 loss per share (vs US$0.048 loss in FY 2019)

New 90-day high: €4.96

New 90-day low: €3.98

Third quarter earnings released

Trxade Group, Inc. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: €4.18

New 90-day low - €4.76

Trxade Group, Inc. to Report Q2, 2020 Results on Jul 27, 2020